The Top 10 Misconceptions in For-Charge EAPs

Expanded Access Programs (including Early Access Programs, Compassionate Use, and Named Patient Supply) play a critical role in enabling patients to receive potentially life-changing therapies before formal market authorization. Yet, despite their importance, there are still widespread misconceptions about how these programs can and should operate.

At the recent Operationalize Expanded Access Programs Summit in Boston, Peter Ogram, EVP of Global Business Development at Tanner Pharma, joined Harpreet Ram of EVR Consulting LLC to address this challenge head-on.

For biopharmaceutical companies, Expanded Access is not only about providing treatment options—it is also about navigating complex regulatory, operational, and financial considerations. Misunderstandings around for-charge models can create unnecessary barriers, limiting flexibility and delaying patient access.

In reality, these programs can be structured in ways that are both compliant and sustainable when designed correctly. To help clarify these challenges, we’ve outlined ten of the most common misconceptions surrounding for-charge EAPs.

Supporting smarter access strategies

At Tanner Pharma, our Access Solutions are designed to remove barriers and simplify the delivery of critical therapies worldwide. If you would like to explore how for-charge models could fit within your global access strategy, our team is here to help.